Chiong, Edmund and Saad, Marniza and Hamid, Agus Rizal A. H. and Ong-Cornel, Annielyn Beryl and Lojanapiwat, Bannakij and Pripatnanont, Choosak and Serrano, Dennis and Songco, Jaime and Sin, Loh Chit and Hakim, Lukman and Chua, Melvin Lee Kiang and Nguyen, Nguyen Phuc and Phuong, Pham Cam and Patnaik, Ravi Sekhar and Umbas, Rainy and Kanesvaran, Ravindran (2024) Prostate cancer management in Southeast Asian countries: A survey of clinical practice patterns. Therapeutic Advances in Medical Oncology, 16. ISSN 1758-8340, DOI https://doi.org/10.1177/17588359231216582.
Full text not available from this repository.Abstract
Background:Prostate cancer (PC) has a serious public health impact, and its incidence is rising due to the aging population. There is limited evidence and consensus to guide the management of PC in Southeast Asia (SEA). We present real-world data on clinical practice patterns in SEA for advanced PC care.Method:A paper-based survey was used to identify clinical practice patterns and obtain consensus among the panelists. The survey included the demographics of the panelists, the use of clinical guidelines, and clinical practice patterns in the management of advanced PC in SEA.Results:Most panelists (81%) voted prostate-specific antigen (PSA) as the most effective test for early PC diagnosis and risk stratification. Nearly 44% of panelists agreed that prostate-specific membrane antigen positron emission tomography-computed tomography imaging for PC diagnostic and staging information aids local and systemic therapy decisions. The majority of the panel preferred abiraterone acetate (67%) or docetaxel (44%) as first-line therapy for symptomatic mCRPC patients. Abiraterone acetate (50%) is preferred over docetaxel as a first-line treatment in metastatic castration-sensitive prostate cancer patients with high-volume disease. However, the panel did not support the use of abiraterone acetate in non-metastatic castration-resistant prostate cancer (nmCRPC) patients. Apalutamide (75%) is the preferred treatment option for patients with nmCRPC. The cost and availability of modern treatments and technologies are important factors influencing therapeutic decisions. All panelists supported the use of generic versions of approved therapies.Conclusion:The survey results reflect real-world management of advanced PC in a SEA country. These findings could be used to guide local clinical practices and highlight the financial challenges of modern healthcare.
| Item Type: | Article |
|---|---|
| Funders: | Johnson & Johnson International Pte. Ltd. Singapore, EVERSANA India Pvt. Ltd., Mumbai, India |
| Uncontrolled Keywords: | abiraterone acetate; advanced prostate cancer; androgen deprivation; mCRPC; mCSPC; nmCRPC |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine > Clinical Oncology Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 20 Jun 2024 00:35 |
| Last Modified: | 20 Jun 2024 00:35 |
| URI: | http://eprints.um.edu.my/id/eprint/44192 |
Actions (login required)
 |
View Item |
